These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 31142361)

  • 1. The role of
    Hung TJ; McLean L; Mitchell C; Pascoe C; Lawrentschuk N; Murphy DG; Iravani A; Singh D; Hofman MS; Zidan L; Akhurst T; Lewin J; Hicks RJ
    Cancer Imaging; 2019 May; 19(1):28. PubMed ID: 31142361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
    Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
    Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of 18F-FDG PET/CT in Characterization of Equivocal Lesions in High-Risk Testicular Carcinoma in Restaging Setting.
    Rasheed R; Al-Kandari F; Ghanem M; Marafi F; Usmani S
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):511-515. PubMed ID: 32102532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of 18F-FDG PET/CT in the management of testicular cancers.
    Cook GJ; Sohaib A; Huddart RA; Dearnaley DP; Horwich A; Chua S
    Nucl Med Commun; 2015 Jul; 36(7):702-8. PubMed ID: 25757201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group.
    Oechsle K; Hartmann M; Brenner W; Venz S; Weissbach L; Franzius C; Kliesch S; Mueller S; Krege S; Heicappell R; Bares R; Bokemeyer C; de Wit M;
    J Clin Oncol; 2008 Dec; 26(36):5930-5. PubMed ID: 19018083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases.
    Joice GA; Rowe SP; Gorin MA; Pierorazio PM
    Curr Urol Rep; 2018 Nov; 19(12):110. PubMed ID: 30413968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Positron emission tomography in germ cell tumors in men : Possibilities and limitations].
    Schriefer P; Hartmann M; Oechsle K; Meyer CP; Klutmann S; Fisch M; Bokemeyer C; Oing C
    Urologe A; 2019 Apr; 58(4):418-423. PubMed ID: 30374517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
    Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical impact of
    Hart A; Vali R; Marie E; Shaikh F; Shammas A
    Pediatr Radiol; 2017 Oct; 47(11):1508-1513. PubMed ID: 28664453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET in testicular cancer.
    Becherer A
    Methods Mol Biol; 2011; 727():225-41. PubMed ID: 21331937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare "Burned-Out" Testicular Mixed Germ Cell Tumor on 18 F-FDG PET/CT.
    Wu YC; Kao CH; Sun SS; Hsieh TC
    Clin Nucl Med; 2022 Sep; 47(9):e600-e601. PubMed ID: 35085173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
    Spermon JR; De Geus-Oei LF; Kiemeney LA; Witjes JA; Oyen WJ
    BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients.
    Cremerius U; Wildberger JE; Borchers H; Zimny M; Jakse G; Günther RW; Buell U
    Urology; 1999 Nov; 54(5):900-4. PubMed ID: 10565755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography and clinical predictors of survival in primary extragonadal germ cell tumors.
    Buchler T; Dusek P; Brisuda A; Simonova K; Fencl P; Jarkovsky J; Babjuk M; Abrahamova J
    Klin Onkol; 2012; 25(3):178-83. PubMed ID: 22724566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET imaging in testicular tumours.
    Calabrò D; Telo S; Ambrosini V
    Curr Opin Urol; 2020 Sep; 30(5):665-671. PubMed ID: 32732623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
    Decoene J; Winter C; Albers P
    Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG-PET probe-guided surgery for recurrent retroperitoneal testicular tumor recurrences.
    de Jong JS; van Ginkel RJ; Slart RH; Lemstra CL; Paans AM; Mulder NH; Hoekstra HJ
    Eur J Surg Oncol; 2010 Nov; 36(11):1092-5. PubMed ID: 20828977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET in the management of germ cell tumor.
    De Giorgi U; Pupi A; Fiorentini G; Rosti G; Marangolo M
    Ann Oncol; 2005 May; 16 Suppl 4():iv90-94. PubMed ID: 15923438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a diagnostic
    Lim CH; Seok HY; Hyun SH; Moon SH; Cho YS; Lee KH; Kim BT; Choi JY
    Clin Radiol; 2019 Mar; 74(3):207-215. PubMed ID: 30638733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
    Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
    Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.